Printer Friendly

WARNER-LAMBERT ACQUIRES FISONS' CONSUMER HEALTH BUSINESS IN AUSTRALIA AND NEW ZEALAND

 MORRIS PLAINS, N.J., July 2 /PRNewswire/ -- Warner-Lambert Company (NYSE: WLA) announced today that it has acquired the consumer health products business of Fisons plc in Australia and New Zealand.
 Lodewijk J.R. de Vink, president and chief operating officer, said Fisons' consumer health operations in Australia and New Zealand, which include the Rosken line of therapeutic skin care products, "represent an excellent synergistic fit with our existing OTC and personal products business in the region." He said the purchase also emphasized the company's commitment to growth through alliance-building, where it has been particularly active in recent months.
 The acquisition provides Warner-Lambert with an entry into the skin care category in the region. The company's product line there will now include therapeutic moisturizer, hand and body moisturizer, lip protector and sun screen products that will continue to be marketed under the well-recognized Rosken trade name. The newly acquired products also include Infacol, the top-selling anti-gas product for infants.
 Warner-Lambert has a strong presence in Australia with its existing pharmaceutical, OTC and personal care products businesses. Among its over-the-counter and personal care brands, the company has strong market positions with a number of products.
 These leading brands include, Benadryl cough/cold, Listerine mouthwash, Myadec multi-vitamin, Ponstan menstrual pain, Sinutab sinusitis and Schick shaving products. Ponstan and Listerine each holds an approximately 50 percent market share.
 In recent weeks, Warner-Lambert has entered into a series of alliances in support of an overall strategy to grow the top line. These include:
 -- completion of the acquisition of Adams S.p.A, creating the second largest confectionery operation in Italy;
 -- formation of a research-based alliance with Jouveinal, wherein Warner-Lambert acquired a 34 percent interest in the French Pharmaceutical firm, and acquisition of most of Wilkinson Sword's worldwide wet shave business. Combined with Warner-Lambert's Schick line, the acquisition creates a $500 million global wet shave business. Moreover, it provides instant access to markets such as the U.K. and Germany -- where the company will now have a "springboard" to launch its consumer products line.
 Warner-Lambert is a worldwide company devoted to discovering, developing, manufacturing and marketing quality health care and consumer products. It employs approximately 35,000 people.
 -0- 7/2/93
 /CONTACT: Peter Wolf, 201-540-6696, or Lisa Wilder, 201-540-2145, or Sandy Horner, 201-540-4268, or (investors) Stephen Mock, 201-540-6916, and Cary Rosansky, 201-540-4874, all of Warner-Lambert/
 (WLA)


CO: Warner-Lambert Company; Fisons plc ST: New Jersey IN: HOU SU: TNM

TS -- NY002 -- 8047 07/02/93 08:06 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 2, 1993
Words:412
Previous Article:HOWTEK APPOINTS KENNARD S. CLOUD PRESIDENT AND CHIEF OPERATING OFFICER
Next Article:LOWER THAN ANTICIPATED PROFITS PREDICTED AT C-COR, FORECASTS FOR FUTURE REMAIN OPTIMISTIC
Topics:


Related Articles
WARNER-LAMBERT SEEKS TO STOP IMITATION OF COOL MINT LISTERINE
WARNER-LAMBERT - CHURCH & DWIGHT ENTER INTO LICENSING AGREEMENT
WARNER-LAMBERT APPOINTS SURINDER KUMAR PRESIDENT, CONSUMER PRODUCTS R&D
WARNER-LAMBERT REPORTS SALES AND EARNINGS; 15 PERCENT EPS GAIN FOR 1992
WARNER-LAMBERT REPORTS FIRST-QUARTER SALES AND EARNINGS
WARNER-LAMBERT BEGINS SHIPPING COGNEX
WARNER-LAMBERT, WELLCOME ENTER OTC JOINT VENTURE
WARNER-LAMBERT REPORTS THIRD-QUARTER SALES AND EARNINGS
LISTERINE BOTTLE HUNT CONTEST WINNERS ANNOUNCED; RETROSPECTIVE OF LISTERINE PRODUCTS DONATED TO THE SMITHSONIAN
Warner-Lambert Raises Quarterly Dividend by 10% to 38 Cents a Share

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters